ChronicleBio, the AI biotech Fidji Simo co-founded, has signed its first pharma partnership: a development agreement with Prolong Pharmaceuticals for a planned Phase 2a trial of at least 40 patients, with first dosing expected in mid-2027, according to the companies’ joint release of 12 November. The deal came about 15 months after ChronicleBio’s public launch on 5 August 2025, by our arithmetic.
Prolong will supply its drug, PP-007, and pay upfront and milestone-based funding for the study, the release says; financial terms were not disclosed. Simo, who left her full-time OpenAI role in July, wrote on X that “going from company creation to first trial in less than two years is pretty cool”, adding that “there’s still a lot of work to be done to prove we can improve patients’ lives”.
Business Pill · Data Flywheel
An evergreen Business Engineer explainer on how product data loops work. It teaches the general idea only and does not discuss ChronicleBio or Prolong.
The key insight: As we read the release, ChronicleBio is selling patient selection rather than a drug: Prolong supplies PP-007 and funds the study, and ChronicleBio’s platform picks the patients, with further payments to ChronicleBio possible if PP-007 advances in ME/CFS.
According to the release, the trial will test PP-007, an investigational intravenous therapy also known as SANGUINATE, in patients with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). The release says the companies plan to evaluate whether giving it during episodes of post-exertional malaise, the condition’s defining symptom, can speed recovery and reduce symptom severity.
The money runs one way first. Under the agreement, the release says, Prolong will supply PP-007 and provide upfront and milestone-based funding to support the study. ChronicleBio “may receive additional payments tied to further development of PP-007 in ME/CFS or related conditions”, the release says. Neither company gave an amount.
Prolong brings a drug with a clinical record. The release says Prolong has evaluated PP-007 in more than 300 individuals across over 12 clinical trials, and that the FDA granted it Breakthrough Therapy Designation in April 2026 for a form of acute ischemic stroke. The release adds that these designations are specific to stroke and do not constitute FDA approval.
ChronicleBio from launch to its first pharma deal: public launch on 5 August 2025 (launch release); 153 terabytes of data and $15 million raised to date (Fortune, 3 August 2026, as reported); the Prolong development agreement and nearly 200 terabytes (joint release, 12 November 2026); first patient dosing of the planned Phase 2a trial, at least 40 patients, expected mid-2027. 15 months is our arithmetic.
What Was Posted on X
And just like that, we have our first clinical trial and pharma partnership in the works! We’re teaming up with Prolong to take the drug they developed for stroke and see if it can help our patients with ME/CFS by increasing oxygen delivery and blood flow. Thanks to the 200TB of data @chroniclebioAI has amassed, combined with our AI engine, we are identifying patients that show hypoxia so we can focus this trial on them. This is really the promise of the company: understanding biology at such a deep level that we can match the exact right patients to the exact right drugs and massively increase the likelihood of success of trials. Going from company creation to first trial in less than two years is pretty cool, but there’s still a lot of work to be done to prove we can improve patients’ lives. One step at a time.
Fidji Simo, ChronicleBio co-founder and director, posted this at 18:50 UTC on 12 November, quoting the company’s announcement. She calls it ChronicleBio’s first clinical trial and pharma partnership and says it went from company creation to first trial in less than two years. This piece quotes her post as her view.
Today we are announcing our first clinical trial. We’re joining forces with Prolong to evaluate a potential treatment for post exertional malaise (PEM) in #MECFS.
Sanguinate is an investigational intravenous therapy designed to deliver oxygen to deprived tissues, support blood flow, and reduce inflammation. The planned multi-site Phase 2a trial will evaluate the drug in at least 40 patients with first dosing expected mid-2027.
Most trials enroll patients based on symptoms alone, but recruitment for this study will leverage ChronicleBio’s proprietary endotype intelligence platform to identify patients whose disease biology suggests they may be more likely to respond.
We are excited for our partnership with Prolong and grateful for the patient community that drives everything we do.
ChronicleBio’s own account announced the Prolong partnership at 18:42 UTC on 12 November: a planned multi-site Phase 2a trial in at least 40 patients, first dosing expected mid-2027, with recruitment through its endotype intelligence platform. The figures in this piece come from the full joint release it links.
Where the AI Comes In
ChronicleBio’s product is patient selection. Its “endotype intelligence platform” applies machine learning to nearly 200 terabytes of multi-omic data from patients with chronic illnesses, and has identified 14 biological subtypes, the release says. One is a subgroup of ME/CFS patients with markers of impaired oxygen delivery, the target of this trial.
The release contrasts this with “traditional ME/CFS trials that enroll patients primarily based on symptoms”. Chief executive Rohit Gupta said the platform lets the company “identify patients whose disease biology suggests impaired oxygen delivery”. Simo described the aim on X as matching “the exact right patients to the exact right drugs”.
The data figure is higher than in August. Then Fortune reported that ChronicleBio had extracted 153 terabytes of data from patient blood samples and had raised $15 million to date; the November release cites nearly 200 terabytes of multi-omic data, which may not be measured the same way. In the same interview Simo said the company had found five sub-diseases; the release now cites 14 biological subtypes, a different term.
Who Runs ChronicleBio
ChronicleBio’s website lists Rohit Gupta as co-founder and CEO, Fidji Simo as co-founder and director, and Rishi Reddy as co-founder and executive chair. Its launch release of 5 August 2025 described Simo as the incoming CEO of OpenAI’s applications division at the time.
As we read the terms, the deal is a test of whether a startup’s patient data can be the asset a drugmaker pays for: the release names no ChronicleBio drug, only its platform and the subgroup it found.
As we read the timeline, the funded trial deal came about 15 months after launch, by our arithmetic, but the release puts first dosing at mid-2027, so the trial result that would test the platform is still ahead.
Rohit Gupta, ChronicleBio CEO, joint release, 12 November 2026
“Our platform enables us to identify patients whose disease biology suggests impaired oxygen delivery, allowing us to evaluate PP-007 in a population most likely to benefit.”
Three Implications
FOR CHRONICLEBIO The release says it may receive additional payments tied to further development of PP-007 in ME/CFS or related conditions.
FOR PROLONG The release says PP-007 has been evaluated in more than 300 individuals across over 12 clinical trials; this would add a new condition.
FOR AI BIOTECH FOUNDERS The release frames AI-based patient selection as the difference from symptom-based ME/CFS trials; amounts were not disclosed.
The framework says: “Each moat is built by a different data pipeline.”
As we read it, ChronicleBio’s pipeline is patient samples turned into multi-omic data, and the Prolong deal is the first time a drugmaker has put money behind it. The framework predates the deal and does not discuss ChronicleBio.
ChronicleBio’s stated data: 153 terabytes extracted from blood samples (Fortune, 3 August 2026, as reported) and nearly 200 terabytes of multi-omic data (joint release, 12 November 2026). The two figures may not measure the same data.
What Is Not Established
The trial is planned, not running: the release puts first patient dosing at mid-2027 and gives no registry number, sites or trial cost. PP-007’s safety and efficacy in ME/CFS have not been established, the release says. Whether AI-picked patients respond better than symptom-picked ones is what the study is meant to test.
In August Simo told Fortune the company would start testing existing drugs on its patient population before the end of the year; the release dates first dosing to mid-2027. We did not contact ChronicleBio or Prolong for this piece.
This Week In The AI Supercycle
The Great Convergence of Capital, Power, and Geopolitics
This week’s issue: for two years the AI build-out was priced as a supply story, and last week as a credit story. This week it was priced as a permission story, and the answer arrived as a cost, not a ban.
About 15 months after launch, by our arithmetic, Fidji Simo’s ChronicleBio has its first pharma partner: the release says Prolong will fund a planned Phase 2a trial of at least 40 ME/CFS patients chosen by ChronicleBio’s AI platform, with first dosing expected in mid-2027 and financial terms undisclosed.
A note on sourcing. We read the joint release from ChronicleBio and Prolong Pharmaceuticals of 12 November 2026 in full on ChronicleBio’s site, and checked that Prolong’s newsroom lists the same release. We read ChronicleBio’s and Fidji Simo’s posts on X of 12 November and Simo’s post of 9 July 2026, ChronicleBio’s website team list and its launch release of 5 August 2025. The 153 terabytes, $15 million raised and five sub-diseases are as reported by Fortune on 3 August 2026.
The 15 months is our arithmetic. This piece reports a business agreement and makes no claim about the drug’s effect. We did not contact ChronicleBio or Prolong.
Gennaro Cuofano is a CRO and tech executive who has worked in AI since late 2015, starting with bringing NLP, natural-language generation, voice and chatbot products to the marketing industry. His background is in law and finance: he holds a Master's degree in Law and an International MBA with an emphasis on corporate finance (LUISS Business School and the University of San Diego, 2012), and worked as a financial analyst at a real-estate investment firm in San Diego and as an assistant controller. His work focuses on business model strategy, business engineering and, more broadly, structural analysis: how companies make money, read from their own filings. He created FourWeekMBA and leads research there and at The Business Engineer, his newsletter on AI and business strategy, with over 95,000 subscribers and more than 1,000 published analyses. His writing has also appeared on Entrepreneur (for example, How to Digitize a Family Business in Europe) and HackerNoon. Find him on LinkedIn and Substack. See how we source.
